The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Viktor Sundberg - Nordea Markets - Analyst
: Hi, and thank you for taking my question. So on the news here that you will start a new Phase IIb trial in pancreatic cancer, I just wanted to get
some more color on what the FDA gave you as feedback before you decided to start this trial. Is there any particular adverse effect that you think
is not well investigated at the different dose levels at the moment?
And what have they said on what doses that should be investigated in this trial? Is it the same 5 to 7.5 mgs per kgs that you have in that poster
here at AACR? Or is it more to the lower levels of 1 to 2.5 mg per kgs that you just show here in the poster? Thank you.
Question: Viktor Sundberg - Nordea Markets - Analyst
: Okay. Thanks for clarifying. That was all from me. Thank you.
Question: Arvid Necander - Carnegie Investment Bank AB - Analyst
: Good morning, and thanks for taking my question. I had a question on the encouraging signal of higher treatment benefit in IL1RAP high patients.
Are you planning for any clinical or translational work to further validate this signal before randomized data emerges?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 23, 2023 / 8:00AM, CANTA.ST - Q1 2023 Cantargia AB Earnings Call
Would you, for example, also expect to have a high IL1RAP expression in the stroma of patients benefiting the most and if these things -- if these
samples are available from CANFOUR? Or are there any other findings that could help you validate your hypothesis before topline data in 2025?
We'll start there. Thanks.
Question: Arvid Necander - Carnegie Investment Bank AB - Analyst
: Okay, great. Thanks. And second being, does the TRIFOUR protocol allow for the same analysis? Can we expect this type of data from that trial as
well?
Question: Arvid Necander - Carnegie Investment Bank AB - Analyst
: Okay, great. And the last question if I may. How optimistic are you about being granted a breakthrough therapy designation in pancreatic cancer
if you would replicate the results you showed in CANFOUR in the randomized study? And will there be any adaptability built into the randomized
study that could allow you to upsize it should data pan out well?
Question: Arvid Necander - Carnegie Investment Bank AB - Analyst
: Okay, great. That was everything from me. Thanks, guys.
Question: Richard Ramanius - Redeye AB - Analyst
: Good morning. I wanted to continue discussion of the IL1RAP. I was thinking it might be interesting to see the results from all trials because you
have enrolled around 250 patients in total in cancers. So are you planning on doing some aggregate study of IL1RAP expression that just cross all
the cancer types you're studying, where it's possible than where you get -- you have with the biopsies?
Question: Richard Ramanius - Redeye AB - Analyst
: And then I had a question about the CAN10 study. Could you say something more about the design of the Phase I? For example, how many patients
do you plan to recruit?
Question: Richard Ramanius - Redeye AB - Analyst
: You mentioned in the conference call that you intended to do the multiple ascending dose part on psoriasis patients. Is that correct?
Question: Richard Ramanius - Redeye AB - Analyst
: And that would also be seven dose levels?
Question: Richard Ramanius - Redeye AB - Analyst
: Yeah, sure. My last question was a financial one. Since you've halted a large number of trials now, I wondered, how does that mean having an effect
on how long your cash will last. Since, for example, you have halted the study of lung cancer patients.
Question: Richard Ramanius - Redeye AB - Analyst
: Okay, thanks. That's all for me. Thanks.
| 
